The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome

Archives of Gynecology and Obstetrics

Volumn 277, Issue 1, 2008, Pages 25-30

  Gul, Ozgur Baris ^a   Somunkiran, Asli ^a   Yucel, Oguz ^a   Demirci, Fuat ^a   Ozdemir, Ismail ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Homocysteine; Oral contraceptive therapy; PCOS

Indexed keywords

DIANE; HOMOCYSTEINE; TESTOSTERONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLICULAR PHASE; HUMAN; MENSTRUAL CYCLE; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; CYPROTERONE ACETATE; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FOLLICULAR PHASE; HOMOCYSTEINE; HUMANS; LIPIDS; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 36348958435     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-007-0401-x     Document Type: Article

References (45)

1. Franks S (1995) Polycystic ovary syndrome. N Eng J Med 333:853-61
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078-3082
3. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908-915
4. ACOG practice bulletin no. 41 (2003) Polycystic ovary syndrome. Int J Gynaecol Obstet 80:335-348
5. Birdsall MA, Farquhar CM, White HD (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32-35
6. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174:1224-1229 discussion 1229-1232
7. Talbott EO, Guzick DS, Sutton-Tyrrell K et al (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
8. Talbott E, Clerici A, Berga SL et al (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51:415-422
9. Yarali H, Yildirir A, Aybar F et al (2001) Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76:511-516
10. Tiras MB, Yalcin R, Noyan V et al (1999) Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14:1949-1952
11. Orio F Jr, Palomba S, Spinelli L et al. (2004) The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696-3701. Erratum in: J Clin Endocrinol Metab 89:5621
12. Auer J, Berent R, Eber B (2001) Homocysteine: a novel risk factor in vascular disease. Coron Health Care 5:89-99
13. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. J Am Med Assoc 274:1049-1057
14. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE (2004) Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 60:560-567
15. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R (2003) Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18:721-727
16. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L (2002) The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 53:157-162
17. Godsland IF, Crook D, Simpson R, et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381
18. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V (1992) Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64-70
19. Gossain VV, Sherma NK, Michelakis AM, Rovner DR (1983) Effect of oral contraceptives on plasma glucose, insulin, and glucagon levels. Am J Obstet Gynecol 147:618-623
20. Obwegeser R, Hohlagschwandtner M, Sinzinger H (1999) Homocysteine-a pathophysiological cornerstone in obstetrical and gynaecological disorders? Hum Reprod Update 5:64-72 Review
21. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19-25
22. Ashwell M, Chinn S, Stalley S, Garrow JS (1982) Female fat distribution-a simple classification based on two circumference measurements. Int J Obes 6:143-152
23. Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
24. American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
25. Legro RS, Urbanek M, Kunselman AR, Leiby BE, Dunaif A (2002) Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril 78:51-57
26. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935
27. Pasquali R, Patton L, Pagotto U, Gambineri A (2005) Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. Minerva Ginecol 57:79-85 Review
28. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
29. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
30. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
31. Randeva HS, Lewandowski KC, Drzewoski J, et al (2002) Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:4496-4501
32. Orio F Jr, Palomba S, Di Biase S, et al (2003) Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:673-679
33. Yilmaz M, Biri A, Bukan N, et al (2005) Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 20:258-263
34. Vryonidou A, Papatheodorou A, Tavridou A, et al (2005) Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:2740-2746
35. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946-951
36. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327-3334
37. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC (2005) Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152:269-275
38. Cibula D, Fanta M, Vrbikova J, et al (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 20:180-184
39. Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729-1737
40. Graham IM, Daly LE, Refsum HM, et al (1997) Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 277:1775-1781
41. Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277-291
42. ESHRE Capri Workshop Group (2001) Ovarian and endometrial function during hormonal contraception. Hum Reprod 16:1527-1535 (review)
43. Merki-Feld GS, Imthurn B, Keller PJ (2002) Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 51:1216-1221
44. Seeger H, Petersen G, Schulte-Wintrop E, Teichmann AT, Mueck AO (2002) Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. Int J Clin Pharmacol Ther 40(4):150-157
45. Ehrmann AD (2005) Polycystic ovary syndrome. N Eng J Med 352:1223-1236